FDA to look at price comparisons in Rx advertising
Anticipating a day when price comparisons may be a key element in prescription drug advertising, the FDA plans to study how best to present price information in physician and direct-to-consumer (DTC) ads without implying that two drugs are interchangeable. The results of the studies could dictate how drugmakers market biosimilars in the U.S.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST